Tesamorelin vs CJC-1295: FDA-Approved vs Research GHRH Analog
Here is how these two compounds compare — based on published research, not marketing claims.
Tesamorelin
110
Indexed Studies
FDA Approved
Evidence Level
Yes
Human Trials
FDA-Approved
FDA Status
CJC-1295
27
Indexed Studies
Animal Studies
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
Tesamorelin and CJC-1295 are both GHRH analogs — they mimic growth hormone-releasing hormone to stimulate GH production from the pituitary. The critical difference: tesamorelin is FDA-approved. CJC-1295 is not. Tesamorelin has completed clinical trials for a specific indication (HIV-associated lipodystrophy). CJC-1295 is used broadly in peptide therapy but has limited formal clinical data.
Key Differences
| Attribute | Tesamorelin | CJC-1295 |
|---|---|---|
| Evidence Level | FDA Approved | Animal Studies |
| Category | GHRH Analog | GHRH Analog |
| Human Data | Extensive. Phase III clinical trials. FDA approval. Post-marketing surveillance data. | A few human pharmacokinetic studies. Much less clinical depth than tesamorelin. |
| Safety Profile | Well-characterized from Phase III trials. Side effects include injection site reactions, joint pain, and peripheral edema. Contraindicated in certain conditions. | Limited but generally favorable. Common side effects include water retention, numbness, and injection site reactions. |
| Key Limitations | Approved only for HIV lipodystrophy. Off-label use for other indications lacks specific regulatory support. | Not FDA-approved. Limited clinical trial data. DAC version creates sustained elevation that may not mimic natural GH patterns. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
Tesamorelin
Synthetic GHRH analog that stimulates pituitary GH release. FDA-approved as Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Also stimulates IGF-1 production.
CJC-1295
Modified GHRH analog. The DAC (Drug Affinity Complex) version extends half-life to days, producing sustained GH elevation. Without DAC, it behaves more like natural GHRH with a shorter duration.
Same receptor, same basic mechanism. Both activate GHRH receptors on the pituitary to stimulate GH release. Tesamorelin has a trans-3-hexenoic acid modification. CJC-1295 DAC has a Drug Affinity Complex for extended duration. The pharmacological difference is in duration and specificity, not fundamental mechanism.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 137 indexed studies. Here are the key findings.
Massive gap. Tesamorelin is L4 with FDA approval, Phase III trials, and post-marketing data. CJC-1295 is L2 with limited pharmacokinetic studies. For regulatory confidence, tesamorelin is in a completely different category.
For an evidence-based GHRH analog with regulatory approval, tesamorelin is the only option.
For broader GH optimization protocols in peptide therapy, CJC-1295 is more commonly used off-label.
For visceral fat reduction with clinical support, tesamorelin has specific trial data.
For cost and accessibility in non-medical contexts, CJC-1295 is more widely available through compounding.
Key Limitations
- •Tesamorelin's approval is specific to HIV lipodystrophy — off-label use lacks regulatory backing.
- •CJC-1295 has very little formal clinical data despite widespread use.
- •Cost and insurance coverage differ significantly.
- •No head-to-head trial exists.
PSI Verdict
SUPPORTED BY EVIDENCE
Tesamorelin reduces visceral fat and stimulates GH release in HIV lipodystrophy patients, demonstrated in Phase III trials leading to FDA approval. CJC-1295 elevates GH and IGF-1 levels in human pharmacokinetic studies.
NOT YET ESTABLISHED
CJC-1295 has not demonstrated efficacy for any specific clinical indication in controlled trials. Whether tesamorelin's lipodystrophy results translate to non-HIV populations is not established by its regulatory data.
CONFIDENCE LEVEL
High for tesamorelin within its approved indication. Low for CJC-1295 — widely used, poorly studied. If you want evidence, tesamorelin has it. If you want accessibility, CJC-1295 provides it.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Tesamorelin
"Tesamorelin is the only FDA-approved peptide that actually reduces belly fat"Supported by published data
"It is better than regular GH for fat loss because it does not cause insulin resistance"Plausible but unproven
"Biohackers are using it off-label for general fat loss"Anecdotal only
CJC-1295
"CJC-1295 with DAC gives you sustained growth hormone elevation for days"Supported by published data
"Stacking CJC-1295 with ipamorelin is the gold standard for GH optimization"Plausible but unproven
"It made me retain water and feel bloated"Supported by published data
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
Tesamorelin
Well-characterized from Phase III trials. Side effects include injection site reactions, joint pain, and peripheral edema. Contraindicated in certain conditions.
CJC-1295
Limited but generally favorable. Common side effects include water retention, numbness, and injection site reactions.
Tesamorelin has extensive safety data from its regulatory program. CJC-1295 has limited safety characterization. For safety confidence, tesamorelin is significantly better documented.
WHAT THE RESEARCH SUGGESTS
Tesamorelin is the regulatory gold standard among GHRH analogs. CJC-1295 is the accessibility alternative. If evidence matters, tesamorelin wins. If the question is practical availability for GH optimization, CJC-1295 is more commonly used.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.